NASDAQ:STTK

Shattuck Labs Competitors

$31.48
-0.20 (-0.63 %)
(As of 04/16/2021 11:00 AM ET)
Add
Compare
Today's Range
$30.76
Now: $31.48
$31.68
50-Day Range
$27.21
MA: $34.31
$42.01
52-Week Range
$17.51
Now: $31.48
$60.52
Volume1,181 shs
Average Volume126,118 shs
Market Capitalization$1.32 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Shattuck Labs (NASDAQ:STTK) Vs. GLPG, BHVN, SAGE, HCM, IMAB, and ARNA

Should you be buying STTK stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Shattuck Labs, including Galapagos (GLPG), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), I-Mab (IMAB), and Arena Pharmaceuticals (ARNA).

Galapagos (NASDAQ:GLPG) and Shattuck Labs (NASDAQ:STTK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

11.2% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Galapagos and Shattuck Labs, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos210502.18
Shattuck Labs00603.00

Galapagos presently has a consensus price target of $143.7273, suggesting a potential upside of 82.05%. Shattuck Labs has a consensus price target of $45.60, suggesting a potential upside of 44.85%. Given Galapagos' higher possible upside, analysts clearly believe Galapagos is more favorable than Shattuck Labs.

Profitability

This table compares Galapagos and Shattuck Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos-70.67%-11.78%-5.58%
Shattuck LabsN/AN/AN/A

Valuation and Earnings

This table compares Galapagos and Shattuck Labs' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion5.15$167.83 million$5.4614.46
Shattuck LabsN/AN/AN/AN/AN/A

Galapagos has higher revenue and earnings than Shattuck Labs.

Summary

Shattuck Labs beats Galapagos on 5 of the 9 factors compared between the two stocks.

Biohaven Pharmaceutical (NYSE:BHVN) and Shattuck Labs (NASDAQ:STTK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Biohaven Pharmaceutical and Shattuck Labs, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical021002.83
Shattuck Labs00603.00

Biohaven Pharmaceutical presently has a consensus target price of $96.4545, suggesting a potential upside of 29.37%. Shattuck Labs has a consensus target price of $45.60, suggesting a potential upside of 44.85%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Biohaven Pharmaceutical.

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Biohaven Pharmaceutical and Shattuck Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Shattuck LabsN/AN/AN/A

Earnings and Valuation

This table compares Biohaven Pharmaceutical and Shattuck Labs' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.83
Shattuck LabsN/AN/AN/AN/AN/A

Summary

Shattuck Labs beats Biohaven Pharmaceutical on 4 of the 7 factors compared between the two stocks.

Shattuck Labs (NASDAQ:STTK) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Shattuck Labs and Sage Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shattuck Labs00603.00
Sage Therapeutics08802.50

Shattuck Labs presently has a consensus target price of $45.60, suggesting a potential upside of 44.85%. Sage Therapeutics has a consensus target price of $87.0625, suggesting a potential upside of 14.36%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe Shattuck Labs is more favorable than Sage Therapeutics.

Profitability

This table compares Shattuck Labs and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shattuck LabsN/AN/AN/A
Sage Therapeutics-7,706.84%-63.81%-56.64%

Earnings & Valuation

This table compares Shattuck Labs and Sage Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shattuck LabsN/AN/AN/AN/AN/A
Sage Therapeutics$6.87 million646.96$-680,240,000.00($13.38)-5.69

Shattuck Labs has higher earnings, but lower revenue than Sage Therapeutics.

Summary

Shattuck Labs beats Sage Therapeutics on 5 of the 7 factors compared between the two stocks.

Shattuck Labs (NASDAQ:STTK) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Valuation & Earnings

This table compares Shattuck Labs and Hutchison China MediTech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shattuck LabsN/AN/AN/AN/AN/A
Hutchison China MediTech$204.89 million20.65$-106,020,000.00($0.80)-36.33

Shattuck Labs has higher earnings, but lower revenue than Hutchison China MediTech.

Profitability

This table compares Shattuck Labs and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shattuck LabsN/AN/AN/A
Hutchison China MediTechN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Shattuck Labs and Hutchison China MediTech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shattuck Labs00603.00
Hutchison China MediTech00203.00

Shattuck Labs presently has a consensus price target of $45.60, suggesting a potential upside of 44.85%. Hutchison China MediTech has a consensus price target of $40.00, suggesting a potential upside of 37.65%. Given Shattuck Labs' higher probable upside, research analysts plainly believe Shattuck Labs is more favorable than Hutchison China MediTech.

Institutional and Insider Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Shattuck Labs (NASDAQ:STTK) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares Shattuck Labs and I-Mab's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shattuck LabsN/AN/AN/AN/AN/A
I-Mab$4.31 million951.50$-208,560,000.00($28.90)-1.97

Shattuck Labs has higher earnings, but lower revenue than I-Mab.

Profitability

This table compares Shattuck Labs and I-Mab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shattuck LabsN/AN/AN/A
I-MabN/AN/AN/A

Institutional & Insider Ownership

16.6% of I-Mab shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Shattuck Labs and I-Mab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shattuck Labs00603.00
I-Mab00403.00

Shattuck Labs presently has a consensus price target of $45.60, indicating a potential upside of 44.85%. I-Mab has a consensus price target of $70.00, indicating a potential upside of 22.81%. Given Shattuck Labs' higher possible upside, analysts clearly believe Shattuck Labs is more favorable than I-Mab.

Shattuck Labs (NASDAQ:STTK) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares Shattuck Labs and Arena Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shattuck LabsN/AN/AN/AN/AN/A
Arena Pharmaceuticals$806.43 million5.02$397.55 million$7.698.72

Arena Pharmaceuticals has higher revenue and earnings than Shattuck Labs.

Insider and Institutional Ownership

89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Shattuck Labs and Arena Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shattuck Labs00603.00
Arena Pharmaceuticals001503.00

Shattuck Labs presently has a consensus price target of $45.60, indicating a potential upside of 44.85%. Arena Pharmaceuticals has a consensus price target of $92.80, indicating a potential upside of 38.34%. Given Shattuck Labs' higher possible upside, equities research analysts plainly believe Shattuck Labs is more favorable than Arena Pharmaceuticals.

Profitability

This table compares Shattuck Labs and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shattuck LabsN/AN/AN/A
Arena PharmaceuticalsN/A-33.17%-30.41%

Summary

Arena Pharmaceuticals beats Shattuck Labs on 4 of the 7 factors compared between the two stocks.


Shattuck Labs Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Galapagos logo
GLPG
Galapagos
1.3$78.95-0.6%$5.20 billion$1.00 billion-11.96Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56-1.7%$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13-0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.06-1.1%$4.28 billion$204.89 million-36.33
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.08-1.4%$4.10 billion$806.43 million-9.50Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$76.06-2.1%$3.99 billion$1.11 billion24.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28-1.4%$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83-2.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.74-4.7%$3.78 billionN/A-21.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.99-2.7%$3.60 billionN/A-6.20Analyst Report
Analyst Revision
News Coverage
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.11-1.3%$3.53 billion$114.62 million-7.71Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62-3.1%$3.47 billion$136.47 million-12.55
LEGN
Legend Biotech
1.2$25.40-1.6%$3.43 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14-0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96-1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.07-1.2%$3.34 billion$26.52 million-8.02
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37-0.5%$3.29 billion$36.13 million-70.70
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$113.23-3.6%$3.17 billionN/A-56.33Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.65-0.6%$3.15 billion$1.17 billion-42.72
Arvinas logo
ARVN
Arvinas
1.5$62.57-0.7%$3.08 billion$42.98 million-24.44
MorphoSys logo
MOR
MorphoSys
0.3$22.75-1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88-5.5%$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.27-1.2%$2.89 billion$901.90 million-23.72
Organogenesis logo
ORGO
Organogenesis
1.0$21.22-6.5%$2.89 billion$260.98 million-353.67
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.43-1.3%$2.85 billion$644.77 million-10.76
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10-2.3%$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18-4.5%$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67-0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.50-2.0%$2.69 billion$306.49 million25.28
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28-3.4%$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78-4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88-1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76-3.6%$2.48 billion$15 million-17.68Unusual Options Activity
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.93-0.0%$2.47 billion$120.28 million-150.43Analyst Report
Decrease in Short Interest
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50-0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$50.89-4.0%$2.41 billion$33.94 million-87.74Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.96-0.2%$2.25 billion$963.01 million13.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.33-2.7%$2.18 billion$23.90 million-18.22Analyst Report
Unusual Options Activity
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$49.10-2.4%$2.06 billionN/A0.00Insider Selling
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$123.42-2.6%$2.03 billionN/A-11.15
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.07-4.0%$2.01 billion$410,000.00-5.88Analyst Report
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.52-2.2%$2.00 billion$103.54 million-19.19Insider Selling
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$60.11-3.8%$2.00 billionN/A-25.58Increase in Short Interest
Amarin logo
AMRN
Amarin
1.6$4.93-1.6%$1.97 billion$429.76 million-98.58Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.15-0.9%$1.97 billionN/A-19.39
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$21.39-3.5%$1.96 billion$34.51 million-18.28Gap Down
MacroGenics logo
MGNX
MacroGenics
1.2$31.60-3.2%$1.95 billion$64.19 million-10.10Decrease in Short Interest
News Coverage
Kura Oncology logo
KURA
Kura Oncology
1.6$28.84-2.2%$1.95 billionN/A-17.69
MORF
Morphic
1.3$54.52-1.6%$1.80 billion$16.98 million-34.95Insider Selling
Decrease in Short Interest
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.